Cargando…

Bivalirudin plus loading dose of cilostazol-based triple-antiplatelet in treatment of non-ST-elevation myocardial infarction following percutaneous coronary intervention

OBJECTIVE: To study the effect of bivalirudin plus loading dose of cilostazol-based triple-antiplatelet therapy strategy in patients undergoing percutaneous coronary intervention (PCI). METHODS: One hundred and fifty-three patients with non-ST-segment elevation myocardial infarction who underwent PC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Mei, Zhang, Guoru, Wang, Yaling, Zhou, Kun, Liu, Tao, Zhang, Yang, Guo, Anjun, An, Yu, Zhang, Xiaodan, Li, Yongjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592053/ https://www.ncbi.nlm.nih.gov/pubmed/26451112 http://dx.doi.org/10.2147/TCRM.S86799

Ejemplares similares

Safety of Bivalirudin Combined with Ticagrelor in the Emergency PCI in Patients with Acute ST-Segment Elevation Myocardial Infarction
por: Wang, Zheng-Dong, et al.
Publicado: (2022)

Efficacy and safety of bivalirudin application during primary percutaneous coronary intervention in older patients with acute ST-segment elevation myocardial infarction
por: Chen, Hongwu, et al.
Publicado: (2020)

Transulnar sheathless percutaneous coronary intervention during bivalirudin infusion in high-risk elderly female with non-ST segment elevation myocardial infarction
por: Summaria, Francesco, et al.
Publicado: (2012)

Bivalirudin in percutaneous coronary intervention
por: Lehman, Sam J, et al.
Publicado: (2006)

Safety of the primary percutaneous coronary intervention strategy combining pre-hospital prasugrel, enoxaparin and in-hospital bivalirudin in acute ST-segment elevation myocardial infarction
por: Viikilä, Juho, et al.
Publicado: (2016)

Comprehensive safety profile evaluation of bivalirudin in Chinese ST-segment elevation myocardial infarction patients receiving percutaneous coronary intervention: a prospective, multicenter, intensive monitoring study
por: Zheng, Haijun, et al.
Publicado: (2022)

Relative efficacy of bivalirudin versus heparin monotherapy in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: a network meta-analysis
por: Kinnaird, Tim, et al.
Publicado: (2013)

Bivalirudin vs. heparin on a background of ticagrelor and aspirin in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A multicenter prospective cohort study
por: Yu, Xiao-Fan, et al.
Publicado: (2022)

Triple Antiplatelet Therapy with Cilostazol and Favorable Early Clinical Outcomes after Acute Myocardial Infarction Compared to Dual Antiplatelet Therapy with Standard or Potent P2Y12 Inhibitors
por: Byun, Sungwook, et al.
Publicado: (2022)

Heparin Versus Bivalirudin in Acute Myocardial Infarction: Unfractionated Heparin Monotherapy Elevated to Primary Treatment in Contemporary Percutaneous Coronary Intervention
por: Centurión, Osmar Antonio
Publicado: (2016)

Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty
por: Shah, Ashish, et al.
Publicado: (2012)

Bivalirudin Versus Heparin During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
por: Patel, Hiten, et al.
Publicado: (2019)

Effectiveness of dual antiplatelet de-escalation therapy on the prognosis of patients with ST segment elevation myocardial infarction undergoing percutaneous coronary intervention
por: Zhao, Zhigang, et al.
Publicado: (2023)

Acute ST-elevation Myocardial Infarction after Upper Gastrointestinal Bleeding: A Clinical Dilemma of Antiplatelet Therapy
por: Xue, Wen-Qiang, et al.
Publicado: (2018)

Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
por: Li, Senjie, et al.
Publicado: (2021)

Dual Antiplatelet Therapy Using Cilostazol in Patients With Stroke and Intracranial Arterial Stenosis
por: Uchiyama, Shinichiro, et al.
Publicado: (2021)

Prognostic implication of systemic inflammatory state on antiplatelet effect in patients after percutaneous coronary intervention for ST-elevation myocardial infarction: A retrospective cohort study
por: Jiang, Hairui, et al.
Publicado: (2021)

Management of ST-elevation myocardial infarction in the setting of anterior epistaxis: focused on antiplatelet and antithrombotic therapies
por: Handoyo, Victoria, et al.
Publicado: (2019)

Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study
por: Adamski, Piotr, et al.
Publicado: (2017)

Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin
por: Ramana, Ravi K, et al.
Publicado: (2008)

Identification of Circular RNA-MicroRNA-Messenger RNA Regulatory Network in Atrial Fibrillation by Integrated Analysis
por: Liu, Tao, et al.
Publicado: (2020)

Dual Antiplatelet Therapy Using Cilostazol With Aspirin or Clopidogrel: Subanalysis of the CSPS.com Trial
por: Hoshino, Haruhiko, et al.
Publicado: (2021)

Risks and Benefits of Thrombolytic, Antiplatelet, and Anticoagulant Therapies for ST Segment Elevation Myocardial Infarction: Systematic Review
por: Nascimento, Bruno Ramos, et al.
Publicado: (2014)

Variation in Practice Regarding Pretreatment With Dual Antiplatelet Therapy for Patients With Non–ST Elevation Myocardial Infarction
por: Shafiq, Ali, et al.
Publicado: (2016)

Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial
por: Zeymer, Uwe, et al.
Publicado: (2014)

Comparison of net adverse clinical events between bivalirudin and heparin as anticoagulants for percutaneous coronary intervention in Chinese patients
por: Chai, Lina, et al.
Publicado: (2023)

The effect of bivalirudin and closure device on bleeding outcomes after percutaneous coronary interventions
por: Dobies, David R, et al.
Publicado: (2014)

Percutaneous coronary intervention in the elderly with ST-segment elevation myocardial infarction
por: Gao, Lei, et al.
Publicado: (2014)

Primary percutaneous coronary intervention for ST elevation myocardial infarction in nonagenarians
por: Petroni, Thibaut, et al.
Publicado: (2016)

Bivalirudin versus Heparin plus Glycoprotein IIb/IIIa Inhibitors in Women Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
por: Xu, Haiyan, et al.
Publicado: (2017)

MiR-223 or miR-126 predicts resistance to dual antiplatelet therapy in patients with ST-elevation myocardial infarction
por: Li, Xiaojing, et al.
Publicado: (2021)

Spinal cord hemorrhage: a rare complication of dual antiplatelet therapy for non-ST elevation myocardial infarction
por: Yu, Xing, et al.
Publicado: (2019)

Ticagrelor or clopidogrel dual antiplatelet therapy following a pharmacoinvasive strategy in ST‐segment elevation myocardial infarction
por: Welsh, Robert C., et al.
Publicado: (2021)

The Rise and Fall of Anticoagulation with Bivalirudin During Percutaneous Coronary Interventions: A Review Article
por: Andreou, Constantinos, et al.
Publicado: (2017)

No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction
por: Gupta, Sanjiv, et al.
Publicado: (2016)

Percutaneous Intervention in ST-Elevation Myocardial Infarction: Culprit-only or Complete Revascularization?
por: Osório, Ana Paula Susin, et al.
Publicado: (2017)

Clinical outcomes of bivalirudin versus heparin in atrial fibrillation patients undergoing percutaneous left atrial appendage occlusion
por: Zhang, Xiaochun, et al.
Publicado: (2021)

The Elevated Soluble ST2 Predicts No-Reflow Phenomenon in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
por: Somuncu, Mustafa Umut, et al.
Publicado: (2019)

Cilostazol combined with P2Y(12) receptor inhibitors: A substitute antiplatelet regimen for aspirin‐intolerant patients undergoing percutaneous coronary stent implantation
por: Zhao, Yikai, et al.
Publicado: (2022)

Association of Antiplatelet Therapy, Including Cilostazol, With Improved Survival in Patients With Moyamoya Disease in a Nationwide Study
por: Seo, Woo‐Keun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5uf8lci05fn0j0udu4u2o2joee